Increased risk of second primary malignancies in patients with mycosis fungoides: A single-center cohort study - 11/02/20
Doi : 10.1016/j.jaad.2019.06.037
Amrita Goyal, MD a, ⁎ 
, Daniel O'Leary, MD b, Kavita Goyal, MD a, Nathan Rubin, MS c, Kimberly Bohjanen, MD a, Maria Hordinsky, MD a, Steven T. Chen, MD, MPH d, Lyn M. Duncan, MD e, Georgios Pongas, MD f, Aleksandr Lazaryan, MD, MPH, PhD g
, Daniel O'Leary, MD b, Kavita Goyal, MD a, Nathan Rubin, MS c, Kimberly Bohjanen, MD a, Maria Hordinsky, MD a, Steven T. Chen, MD, MPH d, Lyn M. Duncan, MD e, Georgios Pongas, MD f, Aleksandr Lazaryan, MD, MPH, PhD g a Department of Dermatology, University of Minnesota, Minneapolis
b Department of Medicine, University of Minnesota, Minneapolis
c Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
d Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
e Dermatopathology Unit, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
f Department of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota
g Department of Hematology-Oncology, Moffitt Cancer Center, Tampa, Florida
∗Reprint requests: Amrita Goyal, MD, 516 Delaware St, SE, Minneapolis, MN 55455516 Delaware St, SEMinneapolisMN55455
| Funding sources: Research reported in this publication was supported by the National Institutes of Health National Cancer Institute (grant P30-CA-77598) using the Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center,University of Minnesota, and by the National Institutes of Health National Center for Advancing Translational Sciences (Award Number UL1-TR-000114), which funded the statistical analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Conflicts of interest: None disclosed. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 3
P. 736-738 - mars 2020 Retour au numéro
Article précédent
- Systemic timolol exposure following topical application to infantile hemangiomas
- Beth A. Drolet, Felix Boakye-Agyeman, Barrie Harper, Kristen Holland, Andrew Lewandowski, Nicole Stefanko, Chiara Melloni, Pediatric Trials Network Steering Committee (See Acknowledgments for a listing of committee members.), Gary Furda, Danny Benjamin, Edmund Capparelli, Gregory L. Kearns, Ian M. Paul, Christoph Hornik, Kelly Wade
- The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
- Antonio Sahuquillo-Torralba, Gregorio Carretero, Raquel Rivera, Carlos Ferrándiz, Esteban Daudén-Tello, Pablo de la Cueva, Francisco José Gómez-García, Isabel Belinchón, Enrique Herrera-Acosta, Diana Ruiz-Genao, Marta Ferrán, Mercé Alsina, Jose Luís Sánchez-Carazo, Ofelia Baniandrés, Lourdes Rodríguez Fernández-Freire, Jaime Vilar, Carmen García-Donoso, Jose Manuel Carrascosa, Mar Llamas-Velasco, Enrique Herrera-Ceballos, José Luis López-Estebaranz, Conrad Pujol-Marco, Miguel Ángel Descalzo, Ignacio García-Doval, Biobadaderm Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?